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Abstract | Skeletal muscle disorders of glycogenolysis and glycolysis account for most of the conditions collectively termed glycogen storage diseases (GSDs) These disorders are rare (incidence 1 in 20,000–43,000 live births), and are caused by autosomal or X-linked recessive mutations that result in a specific enzyme deficiency, leading to the inability to utilize muscle glycogen as an energy substrate. McArdle disease (GSD V) is the most common of these disorders, and is caused by mutations in the gene encoding muscle glycogen phosphorylase. Symptoms of McArdle disease and most other related GSDs include exercise intolerance, muscle contracture, acute rhabdomyolysis, and risk of acute renal failure. Older patient may exhibit muscle wasting and weakness involving the paraspinal muscles and shoulder girdle. For patients with these conditions, engaging with exercise is likely to be beneficial. Diagnosis is frequently delayed owing to the rarity of the conditions and lack of access to appropriate investigations. A few randomized clinical trials have been conducted, some focusing on dietary modification, although the quality of the evidence is low and no specific recommendations can yet be made. The development of EUROMAC, an international registry for these disorders, should improve our knowledge of their natural histories and provide a platform for future clinical trials.

Introduction
Physical activity is inherent to the human condition and, hence, to normal daily existence for every individual on the planet. Even the most economical physical activity requires that skeletal muscle has adequate supplies of substrate to fuel energy demand. As a result, evolution has fostered the development of sophisticated energy management via metabolic processes, whether for the most basic tasks of everyday living, such as personal hygiene and paid work, to achieving the pinnacle of human sporting prowess, a gold medal at the Olympic Games. 
Numerous pathogenic genetic variants affecting enzymes of carbohydrate metabolism and synthesis have been identified, and these variants result in glycogen storage disorders (GSDs), which have a combined incidence of 1 in 20,000 to 1 in 43,000 live births1. In this Review, we focus on muscle disorders caused by enzyme deficiencies associated with glycolysis and glycogenolysis (TABLE 1), which account for the majority of the GSDs. The lysosomal GSDs, including Pompe disease (GSD II), have been reviewed previously,2 and will not be covered here. 
Carbohydrate is a major substrate in mammalian metabolism, and reduced access to stored carbohydrate results in pathologically restricted physical activity. For the purposes of this article, physical activity is considered an umbrella term, embracing all forms of activity from ‘non-exercise activity thermogenesis’ (NEAT)3—that is, activity that is incidental to everyday living—to ‘exercise’, which, by contrast, is the deliberate, planned implementation of physical activity that has a defined purpose (for example, to improve the level of conditioning, and or to improve health status). 
Deficiencies of the enzymes involved in glycogen synthesis and metabolism not only have implications for the capacity to carry out muscular work, but are also associated with additional signs and symptoms that can affect functionality, health and future disease risk. An important consideration that can aid clinical diagnosis of these conditions is that the enzyme deficiency affects all skeletal muscles; thus, symptoms are not confined to the legs, but also affect the face, neck, arms and trunk. Each specific condition has general features that can aid diagnosis and management, once a sufficient physiological and pathological profile has been compiled. 
Even for the most common of these disorders, McArdle disease (GSD V), knowledge and understanding is not widespread across the medical community and, hence, diagnosis has traditionally been slow, with the majority of affected individuals only receiving the correct diagnosis 20 years, on average, after their first presentation to a clinician4. To address this knowledge gap, a European database, EUROMAC, has been established to pool research findings more effectively and translate them into practice. 

The glycogen storage diseases
The nomenclature of GSDs generally follows two principles. Some are named after the individual who first described the condition, and are also assigned a GSD number based on the chronological order of their description (with the exception of the disorder of glycogen synthesis GSD 0). In other cases, particularly relating to exceptionally rare GSDs, the deficient enzyme is used.
The most common feature of the muscle-related GSDs is exercise intolerance, which is usually accompanied by discomfort muscle weakness and/or pain, and, when combined with persistent exercise despite the symptoms, leads to muscle damage, which often manifests as myoglobinuria. The degree of exercise intolerance is extremely variable, even within one specific GSD. In McArdle disease, for example, the distance that affected individuals can walk in a 12 min walk test (12-MWT) varies from around 300–1200 m. The lower end of this range (below 600 m) corresponds to severe incapacity with difficulty completing normal everyday tasks. At the other end of the spectrum is mild intolerance, where, with careful self-management (for example, appropriate ‘warm-up’ prior to exercise, and slowing down or resting until pain subsides during exercise), the patient can be highly functional.




McArdle disease was first described by Brian McArdle in 1951 in a patient who failed to produce lactate during ischaemic exercise,6 and is the result of autosomal recessive mutations in PYGM, the gene encoding the muscle form of glycogen phosphorylase7. In the UK, Northern Europe and USA, most affected individuals have the homozygous or compound heterozygous nonsense mutation Arg50X (originally described as Arg49X), although at least 147 pathogenic mutations and 39 polymorphisms have been described to date8. The prevalence of McArdle disease is believed to be in the region of 1 in 100,000 to 1 in 167,000, but precise epidemiological data are lacking9,10. Affected individuals are deficient in muscle glycogen phosphorylase, which normally catalyses the first step in the conversion of muscle glycogen to glucose-6-phosphate in the Embden–Meyerhof–Parnas (glycolytic) pathway (FIG. 1). Interestingly, patients with a rare splice site mutation resulting in a small amount of residual enzyme (1.0–2.5%) have been described with a milder phenotype that is only evident on exercise testing.11 This finding suggests that very low levels of muscle glycogen phosphorylase are sufficient to ameliorate symptoms — an important consideration for possible therapeutic strategies in the future.

Histopathology
Typically, ~500g of carbohydrate — ~400 g of muscle glycogen, ~100 g of liver glycogen and ~3 g of glucose circulating in the bloodstream — is available for use in individuals without pathology (FIG. 2), but people with McArdle disease have access to just 20% of this carbohydrate12. As a consequence, abnormal storage of muscle glycogen occurs in the form of subsarcolemmal vacuoles that are visible on muscle histology (FIG. 3a). Histochemistry reveals absence of muscle glycogen phosphorylase, although residual staining of the fetal/brain isoform can be seen in the smooth muscle of blood vessels (FIG. 3b). Care must be taken when the diagnosis rests on a muscle biopsy alone, as tissue taken during an episode of acute rhabdomyolysis may stain positively for the glycogen phosphorylase due to expression of the fetal isoform. In addition, histochemical staining of glycogen phosphorylase depends on the presence of glycogen, and in patients who are critically ill, or in the case of a defect in glycogen synthesis, glycogen depletion might lead to absence of staining for the enzyme and, therefore, a false-positive diagnosis13,14.

Pathophysiology
At the start of aerobic exercise, such as walking, muscle contraction is fuelled by ATP already attached within the muscle fibre. ATP is hydrolysed to ADP, and the breaking of a phosphate bond provides the free energy for the ‘power stroke’, with actual movement seen in the shortening of the sarcomere (the ‘sliding filament theory’ — the accepted mechanism of muscle contraction15,16). ATP is reconstituted from intramuscular stores of creatine phosphate by donation of an inorganic phosphate group. However, this process is soon outstripped by demand, and people with McArdle disease are unable to mobilize ATP from other sources, leading to an energy crisis that causes the heart rate to increase sharply, together with symptoms of discomfort, pain and fatigue in the exercising muscle. The patient must, therefore, slow down or to stop the activity, allowing the symptoms to subside or disappear before exercise can continue. 
On recommencement of physical activity, the symptoms may reappear but should soon diminish, alongside a decrease in heart rate (at 8–10 min into continuous physical activity), as a result of an augmented supply of ATP associated with increased efficiency of fat oxidation and improved muscle blood supply. The 8–10 min lag represents the time taken to increase the rate of fat oxidation to an appropriate level to meet a relatively modest demand, with respect to intensity of effort. The abrupt easing of symptoms and attendant sudden increase in exercise capacity is known as the ‘second wind’ phenomenon17, and is considered to be a pathognomonic feature of McArdle disease18. With increasing exercise intensity, individuals with this disease fail to exhibit the normal physiological rise in levels of blood lactate (FIG. 4), which is an important fuel source during exercise19,20.
Without careful management during the early stages of physical activity to ensure that the second wind is achieved, individuals with McArdle disease are at substantial risk of contracture and rhabdomyolysis. Muscle contracture is a type of muscle cramp that is electrically silent21, and is a common feature of McArdle disease, leading to muscle damage and rhabdomyolysis4. As a consequence, when exercise assessments are performed in this patient population, on an exercise bike18 or treadmill, or via the 12-MWT in a corridor22, heart rate is generally monitored alongside the use of the Borg CR10 Rating of Perceived Pain (RPP) scale or the Borg Rating of Perceived Exertion (RPE)23. 
The 12-MWT is a useful measure that can be undertaken in a clinical setting without the need for specialist equipment. Immediately prior to commencement of the test, the RPP scale is explained to the patient, so as to anchor the ends of the range descriptors. During exercise testing, efforts are made to ensure that pain does not exceed a rating of ‘4’, as higher levels are consistent with the onset of muscle contracture. Testing of this type should occur on a regular basis for clinical monitoring, with the total distance walked being recorded as an outcome measure of current level of function and to monitor improved function between successive test periods. Monitoring of the heart rate every minute during the test often reveals the second wind phenomenon22. A functional cycle test can also be very useful for monitoring patients, as well as providing a highly useful and validated outcome measure for research studies18, but it requires specialist equipment and trained staff.

Management: the role of exercise 
Optimum clinical management of McArdle disease includes prescription of exercise designed to increase both function and capacity for physical activity while minimizing the acute risk of contracture. The long-term objective is increased ease of daily function with lower health risk and, consequently, improved quality of life. This goal can be achieved by instructing patients on how to reach a second wind for each muscle group, and by setting short-term goals. The first major aim is to comply with the minimum recommended guidelines for exercise for health of 150 min per week, distributed over 5 days per week at moderate intensity 24,25. The benefits of regular exercise are well known, and increased levels of physical conditioning (‘fitness’) correlate closely with reduced health risks26,27. Even a modest improvement in physical conditioning (1 ml/kg per min improvement in VO2 max28,29 or 1 MET improvement in exercise capacity30) can result in a 10–12% reduction in health risks and all-cause mortality.
In a number of other pathologies, including heart disease and type 2 diabetes, evidence is accumulating that higher-intensity exercise (particularly aerobic high-intensity interval exercise) is efficacious for amelioration of symptoms and to improve function32-37. For many years, testing of peak oxygen uptake (VO2 peak) was generally avoided in people with McArdle disease for fear that the required high intensity of effort would increase the incidence of adverse events such as contracture, rhabdomyolysis, renal failure and attendant increased mortality risk. However, in Spain, testing of VO2 peak in people with McArdle disease has occurred since 2006, and is challenging this perception. Data collected on 81 participants, all with a diagnosis of McArdle disease, have shown significant positive correlations between cardiorespiratory ‘fitness’ (VO2 peak) and quality of life, and an inverse relationship with severity of impairment38. These findings suggest that people with McArdle disease benefit generally from being sufficiently active to improve cardiorespiratory conditioning, and some may be able to adapt to tolerate higher-intensity efforts, thereby further reducing the risks associated with their pathology. 
In one study, eight patients with McArdle disease trained at 60–70% of peak heart rate during 30–40 min cycling sessions 4 days per week for 14 weeks39. Over the course of the study, the participants demonstrated a 36% improvement in peak work capacity, as well as improvements in peak cardiac output, and indicators of improved muscle oxidative capacity, including increased citrate synthase and β-hydroxyacyl coenzyme A dehydrogenase levels.
Although physical activity is undoubtedly beneficial in patients with McArdle disease, the perceived risk of moderate-intensity to high-intensity exercise is high. The suggestion that it is possible for these individuals to exercise at higher intensities and to perform resistance exercise (weight training) is contentious because of the high risk of acute rhabdomyolysis. Nevertheless, resistance training — albeit under close supervision — has been successfully implemented in people with this condition31. 
Santalla et al.40 recently administered a 4 month resistance training programme in seven adults with genetically confirmed McArdle disease. After undergoing two sessions of instruction to ensure that they could safely undertake weight lifting, the participants trained twice a week at the same venue, always under supervision. Power velocity curves were constructed for each patient for half squat (lower body assessment) and bench press (upper body assessment) exercises before and after the 4 month training intervention. A significant increase in lean mass was noted, and significant improvements in muscle strength for both upper and lower extremities (mean improvement 52 W and 173 W, respectively) were demonstrated without any serious adverse events. As a consequence, all patients saw a change to a lower severity class for their disease. Clinical improvements persisted even after a detraining period, with all participants being classed as mild for disease severity. 
These findings suggest that resistance training could be an extremely useful adjunct to aerobic exercise, since individuals with McArdle disease are known to have difficulty increasing their muscle mass. As a consequence, with advancing age, muscle atrophy and weakness occurs, especially involving the shoulder girdle and paraspinal muscles. In addition, semiacute muscle atrophy following injury can become permanent. It should be noted that implementation of the resistance training approach could have substantial financial and staff resource implications, owing to the requirement for appropriately qualified and experienced staff to closely supervise every training session.  

Investigation of New treatment approaches
A number of approaches are being explored with respect to potential treatment of McArdle disease, including dietary manipulation in patients, and testing of more-invasive interventions in animal models of the disease41,42. 

Diet
Creatine supplementation has been used to enhance purine nucleotide cycling in patients with McArdle disease. Although the supplement did increase creatine kinase activity, at high doses it caused increased pain and inhibited tasks of everyday living41, and the subsequent consensus was that the approach had no clinical benefit42.
In a study involving 12 patients with McArdle disease, ingestion of sucrose (75 g in 660 ml solution, 40 min before exercise) increased mean blood glucose levels by more than 2 mmol/l, and resulted in a large reduction in RPE scores and a 34 bpm mean reduction in peak heart rate during exercise on a cycle ergometer43. Further studies confirmed that sucrose or fructose can improve exercise tolerance and capacity and increase well-being, and may reduce the risk of exertional rhabdomyolysis in individuals with McArdle disease43-45.
As people with McArdle disease cannot access the majority of their endogenous carbohydrate stores, and have ‘exaggerated’ lipid oxidation46, there has been speculation as to the potential benefits of a ketogenic diet in these patients47. Indeed, anecdotal reports from individual patients who have tried this approach indicate improved exercise capacity and reduced incidence and magnitude of symptoms. Further studies, including randomized controlled trials, are now required to objectively test these subjective findings.

Animal models
A number of animal models, including bovine, ovine and murine models, are available for further research on potential therapies for McArdle disease48. In one study, notexin, a myotoxin derived from the venom of the Australian tiger snake (Notechis scutatus), was injected into the muscle of live sheep with McArdle disease49. Muscle biopsies were taken before injection and 21 days post-injection, and were compared with untreated sheep muscle. Notexin initially caused muscle necrosis, which was followed by regeneration with some fibres expressing both of the non-muscle isoforms of glycogen phosphorylase (fetal/brain and liver), with resultant increased force of muscle contraction and reduced fatigue. The authors concluded that future research should further examine the potential of re-expression of these isoforms as a treatment for McArdle disease.
In a more recent study, sheep with McArdle disease were given sodium valproate, administered systemically via the enteric route50. This drug, which is normally used for the treatment of epilepsy, has histone deacetylase inhibition qualities, which might potentially affect chromatin and gene expression. Although mobility of the animals was unaffected, re-expression of glycogen phosphorylase did occur in a dose-dependent manner, reaching a peak in 2 h. These findings suggest another possible avenue of investigation for treatment of human McArdle disease.

Cori–Forbes disease
Cori–Forbes disease (GSD III) is the result of autosomal recessive mutations in the AGL gene, which result in deficiency of the enzyme amylo-1,6-α-glucosidase, 4-α-glucanotransferase (more commonly referred to as glycogen debranching enzyme). The condition has a prevalence of less than 1 in 100,000. Cori–Forbes disease has four subtypes, IIIa, IIIb, IIIc and IIId, and their existence and the consequent variation in symptoms is explained by tissue differences in enzyme expression. People with type IIIa, who comprise the majority of patients with Cori–Forbes disease, lack the enzyme in both muscle and liver, whereas those with type IIIb (15% of the total population with Cori–Forbes disease) lack the enzyme in the liver only 51. In type IIIa, enzyme deficiency in cardiac muscle leads to late-onset cardiomyopathy52-53.
Cori–Forbes disease usually manifests in infancy or early childhood, with hepatomegaly, hypoglycaemia, and growth retardation that improves with age. In type IIIa, however, progressive skeletal muscle atrophy and weakness, together with cardiomyopathy, develops in adulthood. Serum creatine kinase levels are raised and muscle biopsy shows abnormal glycogen storage51. However, diagnosis can be confirmed without muscle biopsy by measuring enzyme levels in red blood cells and performing confirmatory DNA studies55. Exercise intolerance is a function of both muscle weakness (mainly arising from atrophy and fatigue) and energy deficiency. The energy deficiency arises from the inability to debranch glycogen56 (which is partially compensated for by increased lipid oxidation, as elucidated by isotopic labelling57), and also from altered peripheral blood flow, which contributes to slowing of recovery58.

Tarui disease
Tarui disease (GSD VII) is named after the Japanese physician Seiichiro Tarui, who first identified phosphofructokinase (PFK) deficiency in 1965 (REF. 59). The condition is caused by mutations in the PFKM gene, which encodes the muscle form of PFK. PFK comprises three distinct subunits, each encoded by a different gene, so mutations in the PFKL (liver type) and PFKP (platelet type) genes are also a possibility60-62. 
In common with other glycolytic disorders, the symptoms of Tarui disease include pain, exercise intolerance, muscle contracture and rhabdomyolysis. However, exercise intolerance tends to be more severe than in McArdle disease, and no second wind has been reported. Indeed, patients describe an ‘out of wind’ phenomenon whereby administration of glucose prior to exercise worsens exercise capacity by ‘blocking’ fatty acid oxidation62. One interesting phenomenon that has been reported is the development of nausea and vomiting with exertion, which has not been described in any of the other related glycolytic disorders. In addition, the glycolytic pathway in red blood cells is affected as a consequence of disrupted calcium homeostasis, so a specific feature of the condition is mild compensated haemolysis62. As in McArdle disease, hyperuricaemia and gout are common features of Tarui disease. Fixed muscle weakness is common with advancing age, and a specific phenotype mimicking limb-girdle muscular dystrophy has been reported. A fatal infantile form associated with arthrogryposis and brain malformation has been reported, but seems to be a distinct genetic entity63.
	Tarui disease is a very rare condition, with only around 100 patients reported in the literature to date. It is especially prevalent among individuals of Ashkenazi Jewish origin and/or those of consanguineous heritage64. The disease is more common in dogs65, which may, therefore, represent a good animal model for future study. 
Prescription of exercise in patients with Tarui disease is likely to be beneficial, although no clinical trials have been conducted. In this population, more-frequent pauses are likely to be required owing to the lack of a second wind phenomenon. Exercise prescription must be tailored to the condition and, from our own experience, the best advice may be ‘little and often’. In practice, this may mean utilizing stored ATP during very short (6 s) bouts of exercise interspersed with 10–20 s rests. This strategy, which is used in our own clinical practice, is based on an established doctrine in sports and exercise physiology, whereby 6–10 s worth of stored ATP can be utilized for bursts of energy. We do not yet know whether this exercise format imposes stimuli of sufficient intensity and duration to encourage beneficial adaptation, in terms of both function and reduced risk of secondary diseases of hypokinesis (such as type II diabetes and heart disease). Potential areas of future research are to determine acute responses to exercise, and to identify any chronic adaptation resulting from exercise that may improve function and quality of life.

Phosphorylase b kinase deficiency
Phosphorylase b kinase deficiency (GSD IX) has an overall prevalence of around 1 in 100,000 (REF. 66), and is characterized by deficiency of phosphorylase b kinase in muscle and/or liver. The normal function of this enzyme is to convert the inactive form of phosphorylase (phosphorylase b) to its active form (phosphorylase a) (FIG. 1). Phosphorylase b kinase deficiency results in four different conditions (GSD types IXa, IXb, IXc and IXd), reflecting the fact that the enzyme is a tetramer of four protein subunits (α, β, γ and δ), each being encoded by a separate gene.
Phosphorylase b kinase deficiency was first described in the 1960s (REF. 67), and is caused by mutations of the PHKA1, PHKA2, PHKB or PHKG2 genes that show an autosomal recessive or X-linked pattern of inheritance68. As females have two X chromosomes but one is subject to X-inactivation69, which is random such that some cells have one of the X chromosomes activated while others have the other one inactivated, it is extremely difficult to predict expression or anticipate symptoms, as a multitude of permutations are possible. Females with a disease allele on one activated locus of X chromosome are carriers of the disease, but they only experience symptoms of the disease themselves if the mutated allele is active in a large percentage of cells. For both manifesting carriers and those inheriting the condition, considerable genetic variation is observed, which greatly increases the range of possible phenotypic expression. Accordingly, symptoms can range from mild to severe.





β-Enolase deficiency (GSD XIII) is a very rare disorder of the enzyme that catalyses the conversion of 2-phosphoglycerate to phosphoenolpyruvate (intermediaries of the Embden–Meyerhof–Parnas pathway) (FIG. 1), and was first reported by Comi et al. in 2001 (REF. 72). Only two papers have been published on this condition, describing just three patients in total72,73. Autosomal recessive mutations in ENO3 are responsible for the documented cases to date73; however, other gene mutations may be possible, as β-enolase comprises three subunits (α, β, and γ), each encoded by a different gene. The α subunit has been identified in many different tissues, whereas the β subunit is mostly found in muscle and the γ subunit mainly in nervous tissue74. 
β-Enolase deficiency is milder than McArdle disease, and the symptoms include exercise intolerance, myalgia, contracture, generalized muscle weakness after exercise, raised creatine kinase levels, and myoglobinuria. The onset of symptoms is difficult to define, as appreciable problems (substantial rhabdomyolysis) were not reported until middle age in one individual, whereas another patient reported problems since childhood72. 
With the advent of next-generation sequencing to aid diagnosis, it seems likely that milder disorders such as β-enolase deficiency will prove to be more common than previously thought: our centre has just diagnosed a second patient within 18 months of our patient first, one of the two described in the Musumeci et al. paper73. However, with so few patients identified to date, the clinical picture for β-enolase deficiency has yet to be fully elucidated.

Phosphoglucomutase-1 deficiency
Phosphoglucomutase-1 (PGM1) deficiency (GSD XIV) has been described as a cause of exercise intolerance and rhabdomyolysis in adults75, but a novel presentation of this GSD was identified by chance as part of an exome sequencing project to identify the causative mutation in a number of individuals thought to have a disorder of glycosylation76. PGM1 catalyses the bidirectional transfer of phosphate from position 1 to position 6 on glucose. Glucose 1-phosphate and UDP-glucose are closely linked to galactose metabolism, and all of the patients in the new series had abnormal transferrin glycoforms. The clinical features included dysmorphic features, such as cleft palate and bifid uvula, short stature, and accessory thumbs. Other features included raised creatine kinase levels, myopathy, rhabdomyolysis, liver disease, and cardiomyopathy75. Galactose supplementation, at least in vitro, has been shown to correct the defect in glycosylation and, thus, offers a potential therapeutic strategy that is yet to be tested in patients76,77.

Other rare glycolytic disorders
The remaining disorders in the glycolytic pathway are extremely rare, and all present in a similar way with exercise intolerance, with or without episodes of rhabdomyolysis. Phosphoglycerate mutase 2 deficiency (GSD X) is caused by autosomal recessive mutations in PGAM2, and can be associated with tubular aggregates found on muscle biopsy78,79. Most (9 of 14) of the affected individuals reported so far are of African American descent. The symptoms are relatively mild compared with McArdle disease, and are induced only by strenuous physical exertion80,81. 
Phosphoglycerate kinase deficiency has been reported in males presenting with haemolytic anaemia, with or without neurological features including parkinsonism and/or learning difficulties, and myopathy with exercise intolerance82-84. Inheritance is X-linked recessive. In one case, the haemolytic anaemia was severe enough to warrant blood transfusion at a young age before the onset of myopathic symptoms85.
Lactate dehydrogenase A subunit deficiency (GSD XI) was first reported in 1980, and is very rare, with only nine families reported worldwide, six of whom are of Japanese origin. The condition presents with exercise intolerance and myoglobinuria, and some patients exhibit characteristic skin lesions86-88. 

Disorders of glycogen synthesis
Mutations in three genes associated with glycogen synthesis have been linked to GSDs: glycogen synthase 1 (GYS1) mutations cause GSD 0, glycogogenin-1 (GYG1) mutations cause GSD XV (REF. 89), and mutations in RBCK1, which codes for ubiquitin ligase, lead to polyglucosan body myopathy. Although disorders of glycogen synthesis are not related to defects in the glycogenolytic or glycolytic pathway, they are worthy of a brief mention because they can present with severe exercise intolerance, thus mimicking other muscle glycogenoses. Other features include severe cardiomyopathy with sudden death due to arrhythmias, and limb-girdle muscle weakness90-95. Because patients with these disorders lack muscle glycogen, no rise in lactate occurs with exercise, and staining for the enzyme muscle glycogen phosphorylase produces a negative result. Complete absence of glycogen staining, with or without polyglucosan bodies, should alert the pathologist to the possible diagnosis of a disorder of glycogen synthesis13,94.

The EUROMAC registry
EUROMAC (​http:​/​​/​euromacregistry.eu​) is a European Union (EU)-funded registry of patients affected by McArdle disease and other rare diseases of carbohydrate metabolism in which exercise intolerance is the primary symptom. After obtaining informed consent, medical specialists upload their patients’ data onto a secure web platform. The aim is to register as many patients as possible across all European countries, and to record clinical and epidemiological data that will provide insights into the natural history of these disorders and provide a platform for large international clinical trials. 
EUROMAC holds regular events, including an annual symposium where stakeholders, practitioners and patients are invited to contribute in order to record and disseminate knowledge and share best practice. EUROMAC currently comprises 15 partners from seven EU countries, as well as partners from Turkey and North America. The EUROMAC consortium is led by an international group of specialists in the field. In July 2014, a EUROMAC exercise workshop for clinicians and patients, held in Madrid, Spain, demonstrated that resistance training can be performed safely in people with McArdle disease, provided that it is undertaken in a closely supervised and controlled way90. 
EUROMAC aims to raise awareness of these rare disorders, as well as improving diagnosis and management. An international clinical trial is currently underway, examining the effectiveness of sodium valproate as a potential treatment for McArdle disease, as was discussed in detail above. The long-term goals of EUROMAC are listed in BOX 1. 

Summary and conclusions
In summary, the muscle GSDs are associated with exercise-induced symptoms occurring within a few minutes after initiation of aerobic activity, an inability to perform isometric muscle activities, and a risk of muscle contracture, acute rhabdomyolysis and acute renal failure. The presence of additional features, such as haemolytic anaemia, neurological, skin or hepatic symptoms, and/or cardiomyopathy can point to specific enzyme deficiencies and aid diagnosis. No specific treatment is available for any of these disorders, but aerobic training with exercise prescription is important to improve fat oxidation through conditioning, and to reduce the attendant health risks of a sedentary lifestyle. Owing to the rarity of these disorders, questions remain about their natural history and the long-term consequences of a sedentary lifestyle. In 2013, EUROMAC, a registry funded by the EU, was established. It is hoped that this registry will provide useful data on the prevalence and natural history of these disorders, as well as providing a platform for future clinical trials90.

Key points
	Of the glycogenolytic and glycolytic disorders (GSDs), McArdle disease (GSD V) is the most common (prevalence 1 in 100,000–167,000), and β-enolase deficiency is the rarest, with only three cases identified to date
	The GSDs result from autosomal or X-linked recessive mutations, resulting in a specific enzyme deficiency that leads to the inability to utilize muscle glycogen as an energy substrate
	The main features of the GSDs include exercise intolerance and myoglobinuria; paradoxically, when appropriately prescribed, exercise can improve work capacity, reduce health risks, ameliorate symptoms and improve quality of life
	Exercise intolerance and hence avoidance which can lead to secondary health threats from a sedentary lifestyle increases health risks generally and further threatens a reduced quality of life
	Additional clinical features, such as dysmorphic features, haemolysis, neurological features, liver disease, skin lesions and/or cardiomyopathy, can help to pinpoint the specific enzyme deficiency
	Potential therapies for McArdle disease are being explored through the use of animal models of the disease (cattle, sheep and mice), and through dietary manipulation and speculative drug therapy in humans
	A European database (EUROMAC) has been established to pool and transfer knowledge regarding McArdle disease and other rare diseases of carbohydrate metabolism more effectively.
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Box 1 | Long-term goals of EUROMAC
	Improved patient access to specialized care
	Involvement of national governments and regulatory agencies
	Improved knowledge of the natural history of McArdle disease and other rare neuromuscular glycogenoses
	Reduced average delay in diagnosis
	Reduced risk of incorrect advice leading to debilitating symptoms and increased risk of life-threatening crises, necessitating admission to critical care

Figure 1 | Enzymatic pathways involved in glycolysis and glycogenolysis. Red ovals indicate enzymes that are affected in various glycogen storage diseases (GSDs).

Figure 2 | Distribution of carbohydrate in the body. In individuals without pathology, carbohydrate is distributed as 400 g of glycogen in muscle, 100 g of glycogen in the liver, and 3 g of glucose in the systemic circulation. In patients with McArdle disease, >400 g of glycogen is stored in muscle, but is unavailable as a fuel substrate, with only liver glycogen and blood glucose being available for metabolism.

Figure 3 | Muscle biopsy from a patient with McArdle disease. a | Haematoxylin and eosin stain, illustrating subsarcolemmal vacuoles with excess glycogen storage. b | Histochemical staining reveals absence of muscle glycogen phosphorylase. The fetal/brain isoform of this enzyme can be seen in the smooth muscle of blood vessels.

Figure 4 | Blood lactate concentration with exercise. With increasing exercise intensity, healthy individuals without pathology demonstrate a rise in blood lactate concentration. By contrast, people with McArdle disease have a normal resting blood lactate concentration, but the level decreases at the start of exercise and remains low throughout, despite increasing exercise intensity.


Table 1 | Skeletal muscle disorders of glycogenolysis, glycolysis and glycogen synthesis
Condition	Enzyme deficiency	Gene	Inheritance	Features
McArdle disease (GSD V)	Glycogen phosphorylase, muscle form	PYGM	AR	Exercise intolerance, myoglobinuria, second wind, goutOlder patients (>40 years) may exhibit wasting and weakness of paraspinal muscles and shoulder girdle
Cori–Forbes disease, (GSD III)	Glycogen debranching enzyme	AGL	AR	Type IIIa: skeletal muscle weakness, cardiomyopathy, liver diseaseTypes IIIb and IIId: liver disease only Type IIIc: skeletal muscle weakness, liver disease
Tarui disease (GSD VII)	Phosphofructokinase	PFKM	AR	Vomiting with exercise, exercise intolerance, myoglobinuria, muscle atrophy and weakness, gout, haemolytic anaemiaNeonatal form with arthrogryposis
GSD IX	Phosphorylase b kinase γ	PHKG1	AR	Not reported
Phosphorylase b kinase α deficiency	Phosphorylase b kinase α, skeletal muscle isoform	PHKA1	AR	Exercise intolerance, myoglobinuria
	Phosphorylase b kinase α, liver isoform	PHKA2	XL	Liver disease, exercise intolerance, myoglobinuria
Phosphorylase b kinase β deficiency	Phosphorylase b kinase β	PHKB	XL	Liver disease, exercise intolerance, myoglobinuria
5′-AMP-activated protein kinase subunit γ2 deficiency 	5′-AMP-activated protein kinase subunit γ2	PRKAG2	AR	Wolff–Parkinson–White syndrome, hypertrophic cardiomyopathy
GSD XIII	β-Enolase	ENO3 	AR	Exercise intolerance, myoglobinuria
GSD XIV	Phosphoglucomutase-1 	PGM1	AR	Dysmorphic syndrome (short stature, cleft palate, bifid uvula), exercise intolerance and myoglobinuria, dilated cardiomyopathy, liver disease, abnormal transferrin glycoforms
GSD X	Phosphoglycerate mutase 2	PGAM2	AR	Exercise intolerance, myoglobinuriaTubular aggregates observed in muscle biopsy
Phosphoglycerate kinase 1 deficiency	Phosphoglycerate kinase 1	PGK1	XL	Exercise intolerance, myoglobinuria, haemolytic anaemia, learning difficulty, parkinsonism
GSD XI	Lactate dehydrogenase	LDHA	AR	Exercise intolerance, myoglobinuria, skin rash
GSD 0	Glycogen synthase 1	GYS1	AR	Exercise intolerance, cardiac arrhythmiaGlycogen depletion, polyglucosan bodies
GSD XV	Glycogenin-1	GYG1	AR	Exercise intolerance, limb-girdle muscle weakness, hypertrophic cardiomyopathyGlycogen depletion, polyglucosan bodies
E3 ubiquitin ligase deficiency	E3 ubiquitin ligase	RBCK1	AR	Rapidly progressive cardiomyopathy, muscle weaknessGlycogen depletion, polyglucosan bodies
AR, autosomal recessive; GSD, glycogen storage disease; XL, X-linked.
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